Cargando…
Tocilizumab in COVID-19: Beware the risk of intestinal perforation
Autores principales: | Vikse, Jens, Henry, Brandon Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204657/ https://www.ncbi.nlm.nih.gov/pubmed/32389721 http://dx.doi.org/10.1016/j.ijantimicag.2020.106009 |
Ejemplares similares
-
Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs
por: Mutua, Victor, et al.
Publicado: (2022) -
Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case()
por: Gonzálvez Guardiola, Paula, et al.
Publicado: (2021) -
Methylprednisolone/tocilizumab: Intestinal perforation following off-label use: case report
Publicado: (2020) -
Methylprednisolone/tocilizumab: Intestinal perforation following off-label use: case report
Publicado: (2021) -
Beware of the second wave of COVID-19
por: Xu, Shunqing, et al.
Publicado: (2020)